Publicaciones en las que colabora con Belén Atienza Mateo (12)

2023

  1. Cranial and extracranial giant cell arteritis do not exhibit differences in the IL6 -174 G/C gene polymorphism

    Clinical and experimental rheumatology, Vol. 41, Núm. 4, pp. 910-915

  2. Cranial and extracranial large-vessel giant cell arteritis share a genetic pattern of interferon-gamma pathway

    Clinical and experimental rheumatology, Vol. 41, Núm. 4, pp. 864-869

2022

  1. Vascular endothelial growth factor haplotypes are associated with severe ischaemic complications in giant cell arteritis regardless of the disease phenotype

    Clinical and experimental rheumatology, Vol. 40, Núm. 4, pp. 727-733

2021

  1. Author Correction: BAFF, APRIL and BAFFR on the pathogenesis of Immunoglobulin-A vasculitis (Scientific Reports, (2021), 11, 1, (11510), 10.1038/s41598-021-91055-z)

    Scientific Reports

  2. BAFF, APRIL and BAFFR on the pathogenesis of Immunoglobulin-A vasculitis

    Scientific Reports, Vol. 11, Núm. 1

  3. Cranial and extracranial giant cell arteritis do not have different HLA-DRB1 and HLA-B association in Caucasian individuals

    Arthritis Research and Therapy

  4. Role of the IL33 and IL1RL1 pathway in the pathogenesis of Immunoglobulin A vasculitis

    Scientific Reports, Vol. 11, Núm. 1

  5. The presence of both HLA-DRB1[*]04:01 and HLA-B[*]15:01 increases the susceptibility to cranial and extracranial giant cell arteritis

    Clinical and experimental rheumatology, Vol. 39, Núm. 2, pp. 21-26

  6. Treatment with tofacitinib in refractory psoriatic arthritis: A national multicenter study of the first 87 patients in clinical practice

    Journal of Rheumatology, Vol. 48, Núm. 10, pp. 1552-1558

2020

  1. Cranial and extracranial giant cell arteritis share similar HLA-DRB1 association

    Seminars in Arthritis and Rheumatism, Vol. 50, Núm. 5, pp. 897-901

  2. Role of IRF5 in the pathogenesis of immunoglobulin-A vasculitis

    Clinical and experimental rheumatology, Vol. 38, Núm. 2, pp. 182-187

  3. Tocilizumab in giant cell arteritis: differences between the GiACTA trial and a multicentre series of patients from the clinical practice

    Clinical and experimental rheumatology, Vol. 38, Núm. 2, pp. 112-119